Detailed analysis of the targets and mechanisms of action of Asnib/Assiminib

Asciminib, trade name: Asciminib, is an innovative oral tyrosine kinase inhibitor (TKI), specifically used for the targeted treatment of chronic myelogenous leukemia (CML). What is unique about it is that unlike traditional ATPcompetitive TKI, asnib binds through the allosteric site (myristoyl pocket) combines withBCR-ABL protein to achieve precise inhibition of tyrosine kinase activity, thereby controlling the abnormal proliferation of leukemia cells. This targeting strategy allows asinib to demonstrate unique efficacy in patients with CML who are resistant or intolerant to first-line TKIs, providing a new option for the treatment of chronic leukemia.

BCR-ABLfusion protein is the core molecular mechanism of CML pathogenesis and is produced by Philadelphia chromosomal translocation. It has a continuously activated tyrosine kinase function and can continuously stimulate downstream signaling pathways, such as the RAS-RAF-MEK-ERK, PI3K-AKT and STAT pathways, thereby promoting tumor cell proliferation, inhibiting apoptosis and enhancing drug resistance. Asnib binds to the myristoyl allosteric site of BCR-ABL to induce conformational changes in the protein and inactivate its tyrosine kinase activity, which is different from traditional TKI< span>The mechanism of competition for ATP binding sites is different, which can overcome drug failure caused by resistance mutations in some ATP binding sites (such as T315I).

At the molecular level, the binding of Asnib to the BCR-ABL allosteric site is highly specific. Through non-covalent binding, the drug can stabilize the auto-inhibitory conformation of BCR-ABL, putting the kinase in a "closed state" and blocking its catalytic activity. This mechanism not only inhibits the proliferation of leukemia cells, but also reduces the inhibition of normal hematopoietic cells, which has certain safety advantages over traditional TKIs. In addition, asinib has been shown in in vitro experiments to have inhibitory activity against a variety of drug-resistant mutant strains, providing the possibility for patients with clinical treatment resistance or failure of multiple lines of treatment.

Clinical studies have shown that asinib can significantly reduce BCR-ABL transcription levels in patients with chronic CML and achieve molecular remission. Its monotherapy can produce lasting effects in patients who are resistant or intolerant to previous TKIs. The main side effects are mild to moderate fatigue, gastrointestinal discomfort and minor abnormalities in hematological indicators. Because its mechanism of action is complementary to traditional TKIs, asinib can also be used in combination with other TKIs to further improve efficacy and delay the development of drug resistance.

The pharmacokinetic characteristics of asinib also support its clinical use. It is well absorbed orally and has high bioavailability. Once daily administration can maintain stable blood concentration. Its metabolism is mainly carried out through the liverCYP3A4 enzyme system, and the excretion pathways include feces and urine. Therefore, attention should be paid to drug interactions with CYP3A inhibitors or inducers during use to avoid abnormal blood concentration affecting efficacy or increasing the risk of adverse reactions.

In general, asinib targets the BCR-ABL protein through the myristoyl allosteric site, inhibits the proliferation of leukemia cells with a unique mechanism of action, overcomes the problem of traditional TKI resistance, and becomes an important treatment option for patients with drug resistance or intolerance of chronic myeloid leukemia. Its precise, efficient and relatively safe targeting properties give it a unique position in the treatment strategy of chronic leukemia. It also provides new ideas and possibilities for future personalized treatment of specific mutant targets.

Reference materials:https://www.drugs.com/